A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.
about
Novel agents in the treatment of multiple myeloma: a review about the futurePotential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancerThe Role of Immunotherapy in Multiple MyelomaMonoclonal antibodies in the treatment of multiple myeloma: current status and future perspectivesWound healing and cancer stem cells: inflammation as a driver of treatment resistance in breast cancerEvolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted TherapiesDevelopment of Novel Immunotherapies for Multiple MyelomaSiltuximab (CNTO 328): a promising option for human malignanciesThe role of SLAMF7 in multiple myeloma: impact on therapy.Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trialProinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms.The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials.Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells.From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis.Clinical development of siltuximab.Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins.Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.Targeting plasma cells: are we any closer to a panacea for diseases of antibody-secreting cells?Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.Emerging antibodies for the treatment of multiple myeloma.Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma.Economic burden of relapsed or refractory multiple myeloma: Results from an international trial.Monoclonal antibody therapy in multiple myeloma.Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.Targeting interlukin-6 to relieve immunosuppression in tumor microenvironment.Emerging drugs and combinations to treat multiple myeloma.Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy.Lenalidomide overcomes the immunosuppression of regulatory CD8+CD28- T-cells.Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation.The presence of monoclonal gammopathy in Ph-negative myeloproliferative neoplasms is associated with a detrimental effect on outcomes.Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.Immunotherapy Strategies Against Multiple Myeloma.Emerging immune targets for the treatment of multiple myeloma.The bone-marrow niche in MDS and MGUS: implications for AML and MM.Targeting the IL-6/JAK/STAT3 signalling axis in cancer.Epithelial-mesenchymal transition and inflammation at the site of the primary tumor.Antibody based immunotherapy for multiple myeloma: it's about time.Interleukin-6 role in head and neck squamous cell carcinoma progression.Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer
P2860
Q26745924-C58F64E3-F842-4951-827F-872AFB3F7C9BQ26769917-EF5D4F2C-ECE5-4D44-8A6B-A72BBC4A724FQ26771144-817E8DA3-76DE-4D4F-8912-0882D8857343Q26799104-B37B6571-5C70-4C0C-8663-712A7A49939AQ27023599-44904E4D-5DF0-4BD9-91ED-8925354C2D00Q27026478-33FC8F89-8941-4A0E-8E86-A763C0D3418BQ28066890-031BB493-6813-492B-AF71-987C63A67E57Q28082572-45F239E8-B754-4FFB-B02E-1A72099E0876Q30249167-DADA10AF-A42D-4147-9A6E-DAAC650D628BQ30275870-01F1B5A9-8C5A-45DB-B6D9-4E99B217AACBQ33429980-036197A2-DEE9-4068-AA77-37477E99AE38Q36150377-1499BCAC-454E-4C4C-889B-5670FE673F38Q37384918-1DCEFE3E-3E6C-41CF-AA18-317D032EF665Q37722551-D919920F-0AB3-46D1-AC76-4F412BCC1DFAQ38336406-DA9F6C4E-D3A8-4408-ABF1-DAFC1FD42F36Q38489678-2A6DBC5A-C6F2-446A-93A5-0E4EE4C05C68Q38601582-6F932A9C-80A6-4E7B-9CBD-00B2EDCBA603Q38658328-B3CA7AF8-99A4-46DA-BFBD-DA2FE176AE88Q38728585-FBDBB146-5CED-4EA7-AF79-71736958864FQ38763837-7FEF3C26-3BB3-4002-BC8D-B8581CEDFE23Q38838239-AC4B12CB-E14E-4421-B767-94D8502B134BQ38853857-0C2C6626-EDBB-46BC-93F6-466561BA3644Q38901317-0F1D6EC8-33A3-480B-8699-9DC15852E3DAQ38956372-DA5656C6-10D6-4F4D-B837-DAEA60AF359FQ39381251-A6C99A8E-F6ED-4894-8C52-1A88C099B320Q39390630-995D6DDF-CFAF-451C-A8FB-2620433D9E30Q41694198-724B4012-02EA-4D74-8DA5-233CDD310ADBQ42288627-E1F829AB-7D33-4EAB-BD8E-E286A4D28D5AQ47112048-1EA055DE-6ACE-484E-8692-BB616A06FCA0Q47409821-0AA664C0-6638-4A02-8249-24FDC6EDD450Q48176112-57D0AE31-5680-4854-B583-061A6724E4A8Q49539698-1C64DF95-2655-482E-913B-8E003167DAB0Q49995864-D30B103A-278A-4503-A4D0-165BBE0B534EQ50025144-3E94B33D-92D8-4D76-8BBF-3F51EB6771EBQ50114615-A971B653-02A1-45AF-976F-13465435EE7CQ50191433-5F0E39CA-AA8F-4EE8-9DDD-20C658585306Q52540247-498A60AB-F181-4F24-BD5E-C1812A43904CQ53349911-D6C12EFA-F17B-4736-AC2D-595F78C39FE7Q55031288-AEA23B58-1797-4107-95C6-CC68DD3731DCQ57115352-D0118A63-CF15-485C-BFBE-BDAE6C1BED44
P2860
A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
A phase 2, randomized, double- ...... r refractory multiple myeloma.
@ast
A phase 2, randomized, double- ...... r refractory multiple myeloma.
@en
type
label
A phase 2, randomized, double- ...... r refractory multiple myeloma.
@ast
A phase 2, randomized, double- ...... r refractory multiple myeloma.
@en
prefLabel
A phase 2, randomized, double- ...... r refractory multiple myeloma.
@ast
A phase 2, randomized, double- ...... r refractory multiple myeloma.
@en
P2093
P2860
P50
P356
P1476
A phase 2, randomized, double- ...... or refractory multiple myeloma
@en
P2093
Alexander Suvorov
Angelo Maiolino
Cathy Williams
Heather Sutherland
Helgi van de Velde
James D Cavenagh
Jean-Franςois Rossi
Joan Bladé
Manjula Reddy
P2860
P356
10.1002/AJH.23868
P577
2015-01-01T00:00:00Z